RxDoctor Payments Data

Daniel Champey, MD

Neurology · Pollocksville, NCNPI 1700836681

Payments from drug & device makers

$1,944in general payments, 2019–2025

Across 120 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$413
  • UCB, Inc.$200
  • Teva Pharmaceuticals USA, Inc.$161
  • Sanofi$151
  • Supernus Pharmaceuticals, Inc.$147
  • Johnson & Johnson$125
  • plus $748 from 20 others

What the payments were for

  • Food & beverage$1,73489%
  • Education$21011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,944 in reported general payments places this provider in the 55th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$185,086
Medicare patients
731
Services billed
8,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine26$238,195
Aimovig AutoinjectorErenumab-Aooe75$71,427
Nurtec OdtRimegepant Sulfate41$64,966
NuplazidPimavanserin Tartrate13$53,957
Dimethyl Fumarate32$51,809
BriviactBrivaracetam33$50,140
OnfiClobazam12$40,282
NeuproRotigotine26$38,731
UbrelvyUbrogepant20$33,201
FingolimodFingolimod Hcl23$32,760
HorizantGabapentin Enacarbil27$30,060
VimpatLacosamide16$16,944
Carbamazepine ErCarbamazepine139$13,517
NamzaricMemantine Hcl/Donepezil Hcl17$12,269
Donepezil Hcl534$12,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$161$238,19526 claims
UCB, Inc.Briviact, Neupro, Vimpat$200$105,81575 claims
PfizerNurtec Odt, Dilantin$32$70,03460 claims
Acadia Pharmaceuticals IncNuplazid$14$53,95713 claims
AbbVieUbrelvy, Namzaric$21$45,47037 claims
Arbor Pharmaceuticals, Inc.Horizant$12$30,06027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 566 neurology providers in North Carolina.

Other neurology in Pollocksville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →